Yes, Lurbinectedin has been granted accelerated approval by the FDA for the treatment of metastatic small cell lung cancer (SCLC) [2]. Lurbinectedin is a chemotherapy drug that works by inhibiting RNA polymerase II, which is essential for the transcription of DNA into RNA. This drug has shown promising results in clinical trials for the treatment of SCLC, which is a type of cancer that is notoriously difficult to treat [2]. However, it is important to note that accelerated approval is granted based on preliminary evidence, and further studies are required to confirm the drug's efficacy and safety [2]. The drug is sold under the brand name Zepzelca [3].

Sources:
[2] FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer. (2020, June 15). Retrieved January 25, 2021, from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
[3] Lurbinectedin. (n.d.). Retrieved January 25, 2021, from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[4] Zepzelca (lurbinectedin) [Package Insert]. (2020). Pharma Mar, S.A.